Is Dermata Therapeutics Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: DRMA) stock is to Strong Buy DRMA stock.
Out of 1 analyst, 1 (100%) are recommending DRMA as a Strong Buy, 0 (0%) are recommending DRMA as a Buy, 0 (0%) are recommending DRMA as a Hold, 0 (0%) are recommending DRMA as a Sell, and 0 (0%) are recommending DRMA as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year DRMA price target, the average DRMA price target is $3.00, with the highest DRMA stock price forecast at $3.00 and the lowest DRMA stock price forecast at $3.00.
The Wall Street analyst predicted that Dermata Therapeutics's share price could reach $3.00 by May 21, 2026. The average Dermata Therapeutics stock price prediction forecasts a potential upside of 321.35% from the current DRMA share price of $0.71.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.